A CSF biomarker profile for AD includes low levels of Aβ42, reflecting Aβ plaque deposits, and high levels of total tau (T-tau) and hyperphosphorylated tau (P-tau), reflecting increased axonal damage and tau pathology, but other biomarkers have also been investigated to aid in early diagnosis, prognosis, and progression of AD (Blennow et al., 2010; Snyder et al., 2014; Tan et al., 2014). This evidence concerns the gene MAPT and Alzheimer disease.